Covalon Announces Participation in APIC Annual Conference & Exposition on June 26 – 28, 2023 in Orlando, Florida
26 Junio 2023 - 6:30AM
Business Wire
Visit booth 612 to discover how Covalon is
setting new standards in compassionate innovation for infection
prevention solutions that deliver tough protection with gentle
care
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:
COV; OTCQX: CVALF), an advanced medical technologies company, today
announced that it is participating in the 2023 APIC Annual
Conference and Exposition in Orlando, Florida from June 26 to 28,
2023. Healthcare providers looking to strengthen their infection
prevention toolkit with patient-centered medical technology should
visit Covalon at booth 612 to learn more about Covalon’s unique
compassionate care solutions.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230626454700/en/
IV Clear® dressing applied to an IV
insertion site, and VALGuard® applied to a line connection.
Contamination of IV setups is a common source of catheter-related
bloodstream infections and require special handling procedures and
protection to minimize health risks to patients. (Photo: Business
Wire)
APIC, the Association for Professionals in Infection Control and
Epidemiology, is the leading professional association for infection
preventionists (IPs), with more than 15,000 members. The conference
brings together more than 3,000 nurses, physicians, public health
professionals, academia, epidemiologists, microbiologists, medical
technologists, and industry to advance knowledge sharing,
collaboration, and scientific innovation in the area of infection
prevention and control.
“Providing patients thorough protection against infections
should not come at the compromise of providing gentle,
compassionate care,” said Ron Hebert, Senior Vice President,
Marketing, Covalon. “Healing shouldn’t hurt, which is why at
Covalon we are laser focused on developing medical technology that
gives patients their best defense against infection, without
causing unnecessary pain, trauma, or tears.”
Covalon representatives will be available to meet with
participants on site. To make an appointment, please contact Ron
Hebert, SVP Marketing, at rhebert@covalon.com.
Covalon’s suite of infection prevention solutions include:
- VALGuard® - an FDA listed, transparent, environmental barrier
designed to protect catheter hubs and line connections from
external contaminants and gross contamination, including body
fluids and other secretions. It incorporates a quick-release pull
strip for fast access to infusion hubs and for easy removal.
- IV Clear® - the world’s only dual-antimicrobial vascular access
dressing that offers complete transparency at and around the
insertion site for easy daily assessment. It also utilizes soft
silicone adhesive technology to minimize skin injuries and preserve
skin barrier functions, and incorporates safe amounts of
antimicrobials, without sacrificing efficacy, to protect against
chemical irritation.
Conference details Dates: Monday, June 26 to Wednesday,
June 28, 2023 Venue: Orange County Convention Center (9800
International Drive, Orlando, FL 32819) Registration:
https://www.mcisemi.com/apic2023
For healthcare providers who are not able to attend the
conference but are interested in learning more about Covalon’s
solutions, visit www.covalon.com or follow Covalon on LinkedIn,
Facebook, Instagram or Twitter.
About Covalon Covalon Technologies Ltd. is a
patient-driven medical device company, built on the relentless
pursuit to help the most vulnerable patients have a better chance
at healing. Through a strong portfolio of patented technologies and
solutions for advanced wound care, infection prevention, and
medical device coatings, we offer innovative, gentler, and more
compassionate options for patients to heal with less infections,
less pain, and better outcomes. Our solutions are designed for
patients and made for care providers. Covalon leverages its
patented medical technology platforms and expertise in two ways:
(i) by developing products that are sold under Covalon’s name; and
(ii) by developing and commercializing medical products for other
medical companies under development and license contracts. The
Company is listed on the TSX Venture Exchange, having the symbol
COV and trades on the OTCQX Market under the symbol CVALF. To learn
more about Covalon, visit our website at www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release may contain forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend", or variations of such words and
phrases or state that certain actions, events, or results “may”,
“could”, “would”, “might”, “will” or “will be taken”, “occur”, or
“be achieved”. In addition, any statements that refer to
expectations, projections or other characterizations of future
events or circumstances contain forward-looking information.
Statements containing forward-looking information are not
historical facts, but instead represent management’s expectations,
estimates, and projections regarding future events. Forward-looking
statements involve risks and uncertainties, including, but not
limited to, the factors described in greater detail in the “Risks
and Uncertainties” section of our management’s discussion and
analysis of financial condition and results of operations for the
year ended September 30, 2022, which is available on the Company’s
profile at www.sedar.com, any of which could cause results,
performance, or achievements to differ materially from the results
discussed or implied in the forward-looking statements. Investors
should not place undue reliance on any forward-looking statements.
The forward-looking statements contained in this news release are
made as of the date of this news release, and the Company assumes
no obligation to update or alter any forward-looking statements,
whether as a result of new information, further events, or
otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230626454700/en/
Brian Pedlar, CEO, Covalon Technologies Ltd. bpedlar@covalon.com
905.568.8400 x 233 Toll-Free: 1.877.711.6055 https://covalon.com/
Twitter: @covalon
Covalon Technologies (TSXV:COV)
Gráfica de Acción Histórica
De Ene 2025 a Feb 2025
Covalon Technologies (TSXV:COV)
Gráfica de Acción Histórica
De Feb 2024 a Feb 2025